We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+56.43%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$172M
AUM Growth
–
Cap. Flow
+$152M
Cap. Flow %
88.14%
Top 10 Hldgs %
34.38%
Holding
84
New
84
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.7M
2
INSM icon
Insmed
INSM
+$6.39M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.26M
4
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$5.25M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 87.83%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
51
Nkarta
NKTX
$150M
$922K 0.54%
+15,000
New +$623K
AKRO
52
DELISTED
Akero Therapeutics
AKRO
$908K 0.53%
+35,179
New +$979K
ISEE
53
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$899K 0.52%
+130,043
New +$832K
BCRX icon
54
BioCryst Pharmaceuticals
BCRX
$2.28B
$820K 0.48%
+110,000
New +$567K
UTHR icon
55
United Therapeutics
UTHR
$25.8B
$814K 0.47%
+5,364
New +$704K
ALXN
56
DELISTED
Alexion Pharmaceuticals
ALXN
$781K 0.45%
+5,000
New +$643K
ARDX icon
57
Ardelyx
ARDX
$1.22B
$776K 0.45%
+120,000
New +$712K
CALA
58
CALL
DELISTED
Calithera Biosciences, Inc
CALA
$737K 0.43%
+7,500
New +$657K
BIIB icon
59
Biogen
BIIB
$30B
$735K 0.43%
+3,000
New +$774K
CNST
60
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$726K 0.42%
+25,200
New +$634K
ATNM icon
61
Actinium Pharmaceuticals
ATNM
$26.3M
$702K 0.41%
+90,000
New +$978K
KALA icon
62
KALA BIO
KALA
$14.1M
$693K 0.4%
+41
New +$771K
SNDX icon
63
Syndax Pharmaceuticals
SNDX
$1.69B
$667K 0.39%
+30,000
New +$622K
EXAS
64
DELISTED
Exact Sciences
EXAS
$662K 0.38%
+5,000
New +$605K
SLNO
65
DELISTED
Soleno Therapeutics
SLNO
$623K 0.36%
+21,520
New +$621K
CYPH
66
Cypherpunk Technologies Inc
CYPH
$62.9M
$619K 0.36%
+27,500
New +$524K
MCRB icon
67
Seres Therapeutics
MCRB
$46.8M
$613K 0.36%
+1,250
New +$732K
GMDA
68
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$594K 0.35%
+70,852
New +$479K
YARW
69
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$552K 0.32%
+97
New +$610K
RCKT icon
70
Rocket Pharmaceuticals
RCKT
$340M
$548K 0.32%
+10,000
New +$365K
PNT
71
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$543K 0.32%
+39,009
New +$542K
ZNTL icon
72
Zentalis Pharmaceuticals
ZNTL
$337M
$519K 0.3%
+10,000
New +$451K
MDNA
73
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$503K 0.29%
+107,536
New +$433K
IOVA icon
74
Iovance Biotherapeutics
IOVA
$1.82B
$464K 0.27%
+10,000
New +$397K
PTGX icon
75
Protagonist Therapeutics
PTGX
$8.79B
$422K 0.25%
+20,910
New +$450K
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Silverarc Capital Management, which disclosed 84 positions worth $172M. Its ten largest holdings account for 34% of the portfolio.

Its largest position is Vericel Corp: 281,346 shares worth $8.69M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, followed by Financials.

  • Silverarc Capital Management's largest Q4 2020 buy was Vericel Corp: 281,346 shares worth $8.69M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $172M portfolio in Q4 2020.
  • Silverarc Capital Management disclosed 84 positions in Q4 2020, its first 13F filing on record.

Based on Silverarc Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.